Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Trial Profile

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efinaconazole (Primary)
  • Indications Onychomycosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Dow Pharmaceutical Sciences
  • Most Recent Events

    • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
    • 01 Apr 2017 Results of post-hoc pooled analysis comparing data for Latino (n=270) versus non-Latino populations (n=1380) of the two pivotal studies (NCT01007708 and NCT01008033), published in the Cutis Journal.
    • 05 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top